BIOGEN INC.
BIOGEN INC. (BIIB): 43 pipeline candidates · 17 upcoming catalysts · ~15 mo cash runway · 37 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
14.9 months
N/A
Lead: Phase 3
43 candidates
17 upcoming, next in ~348d
1 buy · 2 sells (180d)
A transparent, data-derived signal for BIOGEN INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$29.3B
Cash
$3.4B
Quarterly Burn
$1.1B
Runway
14.9 mo
Revenue
$2.5B
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (43 candidates)
| Drug | Phase |
|---|---|
| [89zr]zr-dfo-biib080 | Phase 1 |
| alemtuzumab | — |
| biib059 | Phase 3 |
| BIIB080 | Phase 1 |
| biib091 | Phase 2 |
| BIIB122 | Phase 2 |
| biib142 | Phase 2 |
| dapirolizumab pegol | Phase 3 |
| dimethyl | Phase 3 |
| diroximel | Phase 3 |
Showing 10 of 43 candidates. Sign up for full pipeline.
Upcoming Catalysts (17)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1,000
Total value held
$25.65B
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 19,074,834 | $3.50B |
| blackrock, inc. | 15,974,601 | $2.93B |
| primecap management co/ca/ | 14,757,607 | $2.71B |
| fmr llc | 12,807,541 | $2.35B |
| state street corp | 7,167,922 | $1.31B |
| vanguard portfolio management llc | 6,531,727 | $1.20B |
| geode capital management, llc | 4,342,602 | $793.4M |
| wellington management group llp | 2,961,641 | $543.0M |
| morgan stanley | 2,170,940 | $398.0M |
| aqr capital management llc | 1,923,557 | $346.2M |
Showing top 10 of 1,000 institutional holders of BIOGEN INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BIOGEN INC.'s pipeline?
BIOGEN INC. (BIIB) has 43 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BIOGEN INC.'s lead drug candidate?
BIOGEN INC.'s most advanced tracked candidate is [89zr]zr-dfo-biib080 (Phase 1) for Healthy Volunteer.
What is BIOGEN INC.'s next catalyst?
BIOGEN INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 3 Trial Evaluating the Efficacy an" — expected June 1, 2027.
What is BIOGEN INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BIOGEN INC. has approximately 14.9 months of cash runway.
What is BIOGEN INC.'s market capitalization?
BIOGEN INC.'s market capitalization is approximately $29.3B.
Get the full picture on BIOGEN INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.